JPRN-jRCT2080220504未知3 期
TK-FT Long-Term Administration Study
试验速览
- 阶段
- 3 期
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •1)Patients who were diagnosed with cancer
- •2)Patients who are 20-74 years old at the time of informed consent
- •3)Patients who are managed with opioid maintenance therapy for persistent cancer pain
- •4)Patients who are managed with rescue opioid for breakthrough cancer pain
排除标准
- •1)Patients with uncontrolled or rapidly increasing cancer pain
- •2)Patients with organic encephalopathies such as intracranial hypertension, consciousness disturbed, coma or brain tumour
- •3)Patients with history of convulsive seizure
- •4)Patients with asthma
研究者
相似试验
未知
3 期
TK-642 Long-Term Administration Studyncontrollable cancer painJPRN-jRCT2080221269TEIKOKU SEIYAKU CO., LTD.
已完成
不适用
Duration of Treatment With Tyrosine Kinase Inhibitors in the Treatment of Metastatic Renal Cell CarcinomaRenal Cell CarcinomaNCT01585974Bayer151
进行中（未招募）
1 期
ong-Term Safety and Efficacy Evaluation of amlitelimab in adult participants with moderate to severe atopic dermatitis.EUCTR2021-002344-73-DESanofi-aventis recherche & développement315
进行中（未招募）
1 期
ong-Term Safety and Efficacy Evaluation of amlitelimab in adult participants with moderate to severe atopic dermatitis.EUCTR2021-002344-73-HUSanofi-aventis recherche & développement315
进行中（未招募）
1 期
ong-Term Safety and Efficacy Evaluation of amlitelimab in adult participants with moderate to severe atopic dermatitis.Dermatitis atopicMedDRA version: 20.0Level: PTClassification code 10012438Term: Dermatitis atopicSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2021-002344-73-CZSanofi-aventis recherche & développement315